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Abstract
The pathogenesis of inflammation in the central nervous system (CNS), which contributes to numerous neurodegenerative
diseases and results in encephalopathy and neuroinflammation, is poorly understood. Sphingolipid metabolism plays
a crucial role in maintaining cellular processes in the CNS, and thus mediates the various pathological consequences of
inflammation. For a better understanding of the role of sphingosine kinase activation during neuroinflammation, we
developed a bacterial lipopolysaccharide (LPS)-induced brain injury model. The onset of the inflammatory response was
observed beginning 4 hours after intracerebral injection of LPS into the lateral ventricles of the brain. A comparison of
established neuroinflammatory parameters such as white matter rarefactions, development of cytotoxic edema, astrogliosis,
loss of oligodendrocytes, and major cytokines levels in wild type and knockout mice suggested that the neuroinflammatory
response in SphK12/2 mice was significantly upregulated. At 6 hours after intracerebroventricular injection of LPS in
SphK12/2 mice, the immunoreactivity of the microglia markers and astrocyte marker glial fibrillary acidic protein (GFAP)
were significantly increased, while the oligodendrocyte marker O4 was decreased compared to WT mice. Furthermore,
western blotting data showed increased levels of GFAP. These results suggest that SphK1 activation is involved in the
regulation of LPS induced brain injury.Research Highlights: N Lipopolysaccharide (LPS) intracerebral injection induces severe
neuroinflammation. N Sphingosine kinase 1 deletion worsens the effect of the LPS. N Overexpression of SphK1 might be
a potential new treatment approach to neuroinflammation.
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Introduction
The inflammatory response starts with recognition of viral or
bacterial products and typically plays a defensive role [1,2], but
when these mechanisms are overactive the evoked cascade can be
fatal [3]. In the central nervous system, inflammation with
a bacterial etiology is thought to contribute to numerous
neurological disorders, including Alzheimer disease [4,5], Parkin-
son disease [6], periventricular leukomalacia [7], multiple sclerosis
[8,9], head trauma, spinal cord injury [5] and sepsis [10]. During
neuroinflammation as a first line of defense, the innate immune
system recognizes a limited number of invading pathogens.
Among them is lipopolysaccharide (LPS), an endotoxin which
forms most of the outer membrane of gram-negative bacteria [11].
It has been shown that LPS binding to toll-like receptors (TLR’s)
and clusters of differentiation (CD11 and CD14) [2] activates
a variety of immune cells such as monocytes, macrophages,
leukocytes and neutrophils. In the mammalian immune system,
lipopolysaccharide is recognized by toll-like receptor-4 (TLR4)
[12]. Intracerebral injection of LPS in TLR42/2 mice did not
result in neutrophil activation [13], and mice lacking this receptor
were hyporesponsive to LPS in general [14].
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid
shown to be a key player in cellular lipid metabolism; it also
serves as an important signaling molecule [15,16]. By binding to its
receptors, S1P regulates several physiological functions, including
angiogenesis, vascular permeability, lymphocyte recirculation, cell
differentiation, proliferation, cytokine/chemokine generation and
apoptosis [17,18,19,20]. S1P is generated by the phosphorylation
of sphingosine by sphingosine kinase [17]. There are two types of
sphingosine kinases, type 1 and type 2 (SphK1 and SphK2) [20].
The catalytic domain structure is similar in both kinases, however
SphK2 has additional domains including a nuclear localization
signal (NLS) domain which is present in the N-terminus of SphK2,
as well as a pro-apoptotic BH3 domain and lipid binding domain
[21,22].
In a previous study we demonstrated that in the lung
vasculature, the activation of SphK1 and subsequent S1P
generation plays a barrier-protective role by controlling in-
flammatory responses [23]. We reported a differential role of the
SphK1 and SphK2 in lipid raft signaling and lung injury. In an
LPS induced lung injury model, SphK12/2 mice were much
more susceptible to injury compared to their WT counterparts, as
quantified by multiple parameters including cytokine induction.
Of particular interest, overexpression of WT SphK1 delivered by
adenoviral vector to the lungs protected SphK12/2 mice from
lung injury, and attenuated the severity of the response to LPS.
However, adenoviral overexpression of a SphK kinase-dead
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7mutant, which can also block SphK2 activity in SphK12/2 mice,
further exacerbated the response to LPS as well as the extent of the
lung injury. This suggested that in vascular injury, activation of
SphK1 plays a protective role. In SphK12/2 mice, we have
further shown that LPS induced lung injury was significantly
reduced by S1P injection. Earlier studies by Garcia [24], Peng [25]
and McVerry [26,27] have shown that S1P is barrier protective,
and in different models S1P treatment increased protection against
lung injury.
Recently, the role of both SphKs in immunity and inflammation
has been the main focus of multiple studies [28,29,30,31].
However, these studies are conflicting, suggesting a broader role
for sphingosine kinases in vascular injury. Puneet‘s study published
that inhibition of Sphk1 led to decreased phagocyte production of
endotoxin-induced proinflammatory cytokines [32]. Other studies
showed that inhibition of SphK1 by its inhibitor and/or siRNA
decreased expression of proinflammatory cytokines, such as
TNFa, IL-1b and iNOS, when activated with LPS, microglia
cells released these chemokines [33].
In our study that involved genetically altered SphK12/2
animals, we hypothesize that in the sphingolipid rich environment
of the brain; deletion of SphK1 will have a deleterious effect on the
development of inflammation. To test our hypothesis, brain injury
was induced by direct injection of LPS (1 mg/kg) into the lateral
ventricles. In this study, we demonstrate that SphK12/2 mice
are more vulnerable to the inflammation and injury induced by
LPS. These findings suggest that SphK1 plays a crucial role in
protection from the development of neuroinflammation induced
by intracerebral LPS injection.
Materials and Methods
Animal Protocol
All animal protocols were approved by the Institutional Animal
Care and Use Committees of the Veterans Affairs (VA) Medical
Center and State University of New York (SUNY) Downstate
Medical Center (Protocol ID # 01165; Prom#: 0002).
Genotyping of SphK1 Mutant and Wild Type Mice
Genotyping for the SphK1 alleles was determined by PCR
analysis of genomic mouse DNA isolated from tail biopsies. Total
DNA was extracted by conventional methods and was used as the
template (40 cycles of 94uC for 1 min, 60uC for 1 min, and 72uC
for 1 min with the extension at 72uC for 7 min) with neomycin
cassette forward SphK1 primer (5_TCGTGCTTTACGG-




verse wild type primer (5_AGCATAGTGGTTCACA-
GAAGCTGCCA_3). The expected product sizes for the wild-
type and targeted SphK1 alleles were 500 bp and 340 bp,
respectively.
Animal Protocol Methods
SphK12/2 mice and their counterpart C57BL/6 WT controls
were selected for procedures. 6–12 month old (n=96) of both
sexes were used for the intracerebroventricular injection. All mice
were divided into 4 groups (24 animals per group): wild type saline
injected, wild type LPS injected, SphK12/2 saline injected, and
SphK12/2 LPS injected. LPS from E.coli serotype 0127:B8
(Sigma-Aldrich) was used to induce brain injury, and sterile saline
was used as a control. Mice were anesthetized with a mixture of
ketamine (100 mg/kg) and xylazine (10 mg/kg) diluted in sterile
saline and were placed in a stereotaxic apparatus. Intracerebro-
ventricular injection was performed as previously described [34].
Briefly, a skull incision was made, exposing the bregma. At
a location of AP – (21.0 mm), ML – (1.0 mm), DV – (2 mm) to
the bregma, LPS was administered at a dose of 1 mg/kg body
weight. Control mice were injected in the same location with
sterile saline. Injected volumes were 2.5 ml each. The injection was
completed within 5 minutes, at speed 0.2 ml/min; the glass pipette
was kept in the position for an additional 2 minutes following
injection, and then slowly extracted. The incision was sutured and
mice were kept at 37uC until recovery. All animals survived the
intracerebroventricular injection. Six hours after the injection,
mice were sacrificed either by cervical dislocation and decapitation
for brain tissue preparation for Western Blot, or by transcardiac
perfusion with 0.1 M PBS followed by freshly prepared 4%
paraformaldehyde, 10% sucrose and further incubation of
extracted brains in increasing gradient sucrose solution. 8 micron
thick frozen coronal cryosections of the brain were prepared for
immunohistochemical and histological analysis.
Immunohistochemistry and Histological Examination
For immunohistochemistry, sections were prepared as pre-
viously described [7]. Hematoxylin and Eosin (H&E) staining and
immunohistochemistry (IHC) were performed in consecutive
frozen sections (8 microns). H&E sections were examined using
an upright epifluorescent microscope for any alterations in
morphology. The area of the brain at the level of bregma: 0.74–
1 mm and interaural: 4.39–5 mm was analyzed. Sizes of both
lateral ventricles were measured as areas of a triangle (A=K of
the base x height) (Fig. S1). Total area of the brain section was
taken as a 100 percent and percent taken by lateral ventricles was
calculated.
White matter rarefactions were blindly counted on non-adjacent
sections that had intact cytoarchitechture. Analysis was performed
on the ipsilateral side of the injection. For immunohistochemistry,
sections were incubated in a fixative solution of 4% para-
formaldehyde overnight at 4uC, followed by incubation in 0.3 M
glycine in PBS for 10 minutes to remove autofluorescence.
Sections were then blocked in a buffer containing 10% normal
goat serum, 0.5% BSA and 0.5% Triton X-100 in PBS for 1 hour
at room temperature. Rinsed sections were incubated overnight at
4uC with primary antibody diluted at different ratios in 1% normal
serum, 0.5% BSA and 0.5% Triton X-100 in PBS at 4uC. In order
to detect reactive astrocytes, GFAP antibody (1:300) (Cell
Signaling Technology, Inc., Danvers, MA) was used; to visualize
oligodendrocytes O4 antibody (1:200) (Sigma Aldrich, St.Louis,
MO) was applied; to determine reactive microglia Ferritin Light
Chain antibody (1:50) (SantaCruz, Santa Cruz, CA) and/or CD68
antibody (1:100) (SantaCruz, Santa Cruz, CA) were used. After
washing, sections were incubated with FITC and/or TRITC
conjugated secondary antibodies (1:1000) (Sigma Aldrich,
St.Louis, MO) in the dark for 2 hours at room temperature. To
make sure that gain or loss of staining was not due to higher/lower
number of cells, DAPI (Sigma Aldrich, St.Louis, MO) and/or
propidium iodide stain was applied in order to visualize nuclei of
all cells in the studied area of the mouse brain. Sections were then
washed, dried, mounted, and studied using an upright compound
epifluorescent microscope. Threshold images of series’ of consec-
utive sections were analyzed using NIH published software
ImageJ. Areas for protein expression quantifications were chosen
stereotactically and based on the in situ hybridization database of
Allen institute of brain science (http://www.brain-map.org/).
Expression of astrocytes’ glial fibrillary acidic protein (GFAP),
microglial CD68 and ferritin light chain protein was quantified on
LPS Induced Severe Brain Inflammation
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Oligodendrocytes progenitor cells O4 protein expression was
quantified at the area of lateral piriform cortex on the ipsilateral
side of the injection.
Proteins Extraction and Western Blot Technique
Membrane proteins were prepared using the following protocol
[35]. Brains were harvested and dissected. The tissue was weighed
and homogenized in RIPA buffer (50 mM Tris HCl pH=7.4;
150 mM NaCl; 1 mM PMSF; 0.1%SDS; 1% Triton X-100; 1%
Sodium Deoxycholate) complete with protease inhibitor cocktail
(Sigma Aldrich, St Louis, MO). Homogenization was performed in
short 10 second bursts followed by 5 minute intervals on ice.
Cytoplasmic and nuclear fractions were separated by centrifuga-
tion, followed by determination of protein concentration in
triplicate by a Bio-Rad DC protein assay kit (BioRad, Hercules,
CA). Equal concentrations (30 mg) of proteins were loaded in each
lane of a standard 4–12% SDS polyacrylamide gel. After
electrophoresis, proteins were transferred to a PVDF membrane
(GE Healthcare Life Science, Piscataway, NJ), then blocked in
0.1 M PBS containing 0.1% Tween (PBS-T) and 5% non-fat milk
for 1 hour. The membranes were then incubated overnight in
a primary antibody specific for the protein of interest at 4uC.
Antibodies were diluted at 1:1000–1:10000 ratio in PBS-T
solution containing 0.5% milk. After washing, the immunoblots
were incubated with the appropriate horseradish peroxidase-
labeled secondary antibodies (1:2000) in PBS-T for 2 hours at
room temperature. Monoclonal GFAP antibody was purchased
from Cell Signaling Technology, Inc., Danvers, MA. The final
step was detection by ECL according to manufacturer’s instruc-
tions (Amersham Biosciences, Pittsburgh, PA). Integrated densities
of the bands were quantified using Image J software and calculated
as a ratio of absolute intensity to the intensity of the background.
Statistical Analysis
Data analysis was performed using unpaired two-way ANOVA
or non-parametric Wilcoxon test when appropriate; Bonferroni’s
multiple comparison of the groups was used to test the effects of
the treatment and/or of the gene. Data is presented as means
6SEM. A value of p#0.05 is considered significant.
Results
SphK12/2 Mice Exhibit Severe Edema and Bigger White
Matter Loss as a Result of Intracerebral LPS injection,
Compared to Wild Type
Direct lipopolysaccharide intracerebroventricular injection
leads to much worse neuroinflammatory reactions in the brain,
although it does relax the blood brain barrier function through
loosening of tight junctions when injected intraperitoneally
[36,37]. During neuroinflammation, changes in vascular perme-
ability results in the development of brain edema. Hematoxylin
and eosin (H&E) stained coronal brain sections were carefully
studied under light microscope for any pathological changes. The
difference in the responses to treatment between wild type and
SphK12/2 mice was prominent. In the central nervous system,
the above mentioned neuroinflammatory processes lead to the
enlargement of the lateral ventricles of the brain (Fig. 1A and 1B).
The percent of the area of the lateral ventricles per brain section
was measured and statistically analyzed (Fig. 1C). SphK12/2
LPS (1 mg/kg) injected mice had the largest ventricles among the
four groups of experimental animals, with 10.9860.6177 (11%) in
this group significantly (p,0.0001) higher than in SphK12/2
saline injected 7.4460.4234 (7.2%) and 2 folds higher than in WT
LPS (1 mg/kg) injected mice 4.860.4057 (Fig. 1C). To our
interest, SphK12/2 saline injected animals expressed some
enlargement of the ventricles too (7.4460.4234), which was
significant compared to wild type saline injected group
(3.21960.12) (*p,0.0001). These findings support our hypothesis
that SphK12/2 animals are more susceptible to the injury and
that deletion of it affects the baseline response to LPS.
Leukoaraiosis is a loss of white matter that is usually associated
with vascular risk factors such as hypertension, or in the context of
cognitive impairment [38]. On the other hand, there are several
reports where leukoaraiosis was found to be in a close relationship
with the inflammatory markers [39] and loss of oligodendrocytes,
followed by demyelination [40]. We calculated the percent of
observed white matter rarefactions per taken cortex area. The
process of leukoaraiosis was doubled in SphK12/2 LPS treated
animals (4.460.33) compared to wild type LPS treated group
(2.460.33), **p,0.0001 (Fig. 1D). The fold increase between
saline and LPS (1 mg/kg) injected animals in the wild type group
(10 folds) was almost 2 times bigger than that in knockout group
(6.8 folds) (Fig. 1D). This effect is possibly due to the presence of
the considerable amount of rarefactions observed in SphK12/2
control mice (0.660.04) which is significantly higher than that in
wild type saline treated animals (0.22960.03311). Nevertheless,
the total number of rarefactions in wild type LPS treated animals
was (2.460.33), which we believe is partially due to the presence of
sphingosine kinase 1 and its pro-survival effects.
Observed rapid increases in the sizes of lateral ventricles and the
basal differences between wild type saline injected and SphK12/
2 saline injected animals led to the analysis of these parameters in
naı ¨ve animals. Statistically significant differences were found
between the sizes of the lateral ventricles of wild type and
SphK12/2 (*p=0.0008) animals (Fig. S2). Brain matter of
SphK12/2 animals appeared to be more distorted (Fig. S2),
pointing to the role of SphK1 not only in the exacerbation of the
neuroinflammatory processes, but in neurogenesis as well. These
observation of ventricular enlargement and white matter rarefac-
tions are consistent with the observations of Tauseef et al., who
demonstrated an enhanced pulmonary edema in SphK12/2
animals in response to LPS [41]. The most interesting finding of
our experiment was the presence of enlarged lateral ventricles in
mutant mice who received saline injection as a control; leading us
to consider the possibility of SphK1 as being an important
molecule in the mechanism of neurogenesis, but this observation
needs to be explored further.
SphK12/2 Animals have More Reactive Microglia after
Intracerebral Injection of LPS
Since microglia are considered to be the macrophages of the
brain, in the next experiment we studied reactive microglia that
are highly expressed during neuroinflammation. Resident
microglia of the brain become reactive following various forms
of insult, including chemical trauma and viral and/or bacterial
infection. We used two types of the specific antibodies to detect
reactive microglia: anti-ferritin light chain [42,43] and anti-
CD68, which are clusters of differentiation that are heavily
expressed on the surface of macrophages and microglial cells
across the brain. The interaction of the antibody and proteins
was visualized using secondary antibodies conjugated to TRITC
and FITC, respectively (Fig. 2B and Fig. 2C). The lateral septal
complex brain area was chosen for reactive microglia immuno-
histochemical study (Fig. 2A). When CD68-positive cells were
quantified and the data analyzed, significant increases were only
found in wild type and SphK12/2 animals treated with LPS
(1 mg/kg) (*p=0.0451) (Fig. 3A). Statistical analysis of the
LPS Induced Severe Brain Inflammation
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ferritin light chain antibody showed that treatment with LPS
(1 mg/kg) only had a significant effect (*p=0.0123) in the
SphK12/2 group (Fig. 3B). In addition, statistical interaction
was found (p=0.0357) between groups. In proof of our
hypothesis that deletion of SphK1 has a devastating effect in
the development of the inflammatory processes in the brain,
Bonferroni’s multiple comparison of the groups displayed a very
significant effect between wild type LPS 1 mg/kg and
SPHK12/2 LPS 1 mg/kg group (**p=0.0181), where the
difference was more than 5 folds in the numbers of ferritin-light
chain positive microglia (Fig. 3B).
Mild Astrogliosis in Wild Type mice as Compared to
SphK12/2 Mice
Astrogliosis is another marker of neuroinflammation [44].
Therefore, our next step was to determine the extent of gliosis in
wild type and SphK12/2 mutant mice. Astrogliosis is an
appearance of gemistocytes, which are reactive astrocytes with
enlarged cytoplasm and proliferating processes [45]. Immunohis-
tochemical analysis using the astrocyte specific antibody GFAP
was performed. Wild type and SphK12/2 mice reacted
vigorously to the intracerebral injection of LPS (1 mg/kg) by
expressing more reactive astrocytes, as compared to saline treated
controls (Fig. 4B). Stained slides were inspected under epifluor-
escent microscope, with close attention paid to the lateral septal
Figure 1. Hematoxylin and eosin staining of the frozen sections of the SphK12/2 type mice. (A) Wild type mice underwent the
intracerebral injection of either saline or LPS 1 mg/kg for 6 hours. Frozen sections of the brains were prepared and stained with hematoxylin and
eosin. LPS injected mice exhibit enlarged ventricles (stars) and white matter rarefactions (arrows), two of the neuroinflammation marker.
Magnification of 46,1 0 6 and 206 are shown. (B) Hematoxylin and eosin staining of the frozen sections of the SphK12/2 type mice. Enlarged
ventricles (stars) and white matter rarefactions (arrows) were observed in control SphK12/2 animals, these neuroinflammatory parameters were
increased after LPS injection. Magnification of 46,1 0 6and 206are shown. (C) Two-way ANOVA statistical analysis of the increase of the sizes of the
lateral ventricles. Injection of LPS 1 mg/kg into lateral ventricle of the brain significantly (p,0.0001) affected development of the edema in SphK12/
2 group. When Bonferroni’s multiple comparison was performed, statistical significance was reached between similarly treated, but genetically
different groups, such as wild type LPS 1 mg/kg vs. SphK12/2 LPS 1 mg/kg (*p,0.0001); wild type saline vs. SphK12/2 saline (*p,0.0001). (D)
Statistical analysis of the loss of the white matter in the brains of the animals intracerebroventicularly injected with saline or LPS 1 mg/kg. Statistical
significance was reached after the injection of LPS 1 mg/kg in wild type and SphK12/2 mice (*p,0.0001). SphK1 deletion had a significant effect
(**p,0.0001) in the development of leukoaraiosis.
doi:10.1371/journal.pone.0036475.g001
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a series of thresholded 406magnified images was performed. Wild
type mice exhibited an increase in reactive astrocytes from
26036284.4 in controls to 852162918 in LPS treated animals
(*p,0.05) (Fig. 4B). In SphK12/2 LPS injected mice, reactive
astrocytes were calculated at 1837063972 per taken area, which
was significantly higher (**p,0.0150) than in saline injected group
(44126722) and any wild type group.
When Western blotting was performed using the GFAP
antibody (Fig. 5A) a significant difference was observed in wild
type group between saline and LPS (1 mg/kg) injected animals
(*p,0.0001). SphK12/2 saline injected mice exhibited very
strong expression of GFAP, which was significantly different from
wild type saline animals (**p,0.001), but no significance was
found in SphK12/2 saline vs. SphK12/2 LPS treated group
(Fig. 5B).
The results of western blot analysis pointed to a significant
difference between wild type saline injected and SphK12/2
saline injected animals, thus we tested naı ¨ve animals. Supplemen-
tary Figure 3 shows significant difference in the expression of
GFAP between wild type and SphK12/2 mice (*p,0.0001).
Western blot supported immunohistochemical findings. Expres-
sion of the astrocyte specific protein GFAP was significantly higher
in SphK12/2 naı ¨ve animals as compared to wild type
(**p=0.0047) (Fig. S3C).
The combined results of the reactive astrocytes study support
our hypothesis that SphK12/2 mice are predisposed to the
injury and react even to the injection of the saline by the
expression of the glial fibrillary acidic protein. We believe this is
a result of SphK12/2 animals being in a state of mild
inflammation.
Loss of Oligodendrocytes Due to LPS Induced Injury
Several studies showed that oligodendrocytes and their
progenitors are one of the first types of cells which respond to
lipopolysaccharide treatment [7,46]. Leukoaraiosis is tightly
correlated with a loss of oligodendrocytes too [40]. To further
characterize the neuroinflammatory effect of LPS in wild type and
SphK12/2 mice, we performed immunohistochemical analysis
of frozen brain sections using oligodendrocytes progenitors’
specific antibody O4. The principal function of the oligodendro-
cytes is an insulation of the axons by providing the myelin sheath
that is critical for neuronal signal transduction. A single
Figure 2. Immunohistochemistry of brain sections after intracerebroventricular LPS injection. (A). Lateral septal complex area of the
brain was chosen for the analysis based on in situ hybridization database. Interaural: 4.39 mm: bregma: 0.74 mm. (B). Immunohistochemistry of the
frozen sections of the brains of wild type mice that received intracerebroventricular injection of saline or LPS 1 mg/kg. Reactive microglia was
visualized by double staining with anti-CD68 (FITC – thick arrows) and anti-ferritin light chain (TRITC – arrow heads) antibody. DAPI stain was used to
detect nuclei of all cells. Magnifications of 406are shown. (C). Anti-CD68 (FITC), anti-ferritin light chain (TRITC) positive staining and DAPI staining of
the frozen brain sections of SphK12/2 experimental animals. Magnifications of 406are shown.
doi:10.1371/journal.pone.0036475.g002
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the integrity of these cells is crucial for a normal function of the
brain. Oligodendrocyte progenitor cells are scattered in the brain
tissue; however for immunohistochemical analysis the area of the
piriform cortex was chosen based on the database of Allen brain
atlas of protein expression (Fig. 6A). Loss of oligodendrocytes was
noticeable in WT and SphK12/2 animals after LPS treatment
(Fig. 6B). Frozen sections of the brains of wild type mice were
examined and the number of stained particles was quantified,
using Image J software. In the WT group, the number of stained
particles declined by 3.2 folds from 16026113.3 in saline treated
animals to 494.3646.05 in LPS injected mice (Fig. 6C). SphK12/
2 mice showed 1.9 folds loss of the myelinating cells from
710647.83 in saline injected mice to 360620.98 in LPS injected
mice, respectively (Fig. 6B). The significance in loss of oligoden-
drocytes was reached between wild type saline vs. wild type LPS
1 mg/kg (*p,0.0001) and in wild type saline vs. SphK12/2
saline (**p,0.001) groups. The basal level of quantified oligoden-
drocytes in mutant controls is 2.3 folds less as compared to the wild
type saline treated group (Fig. 6C). These results support our
hypothesis that SphK12/2 mice are more susceptible to LPS
induced brain injury due to the absence of sphingosine kinase 1,
which when present does not allow neuroinflammation to develop
to an extreme level.
Discussion
The primary aim of this study was to determine the
pathophysiological changes in the brain as a result of LPS
challenge, and to determine the role of sphingosine kinase 1
(SphK1) in these changes. The major finding of the study was that
intracerebroventricular injection of LPS (1 mg/kg) induces mor-
phological neuroinflammatory parameters: 1) enlarged lateral
ventricles (Fig. 1); 2) distorted brain matter (Fig. 1); 3) increased
expression of reactive microglial markers, such as CD68 and
ferritin light chain (Fig. 2 and Fig. 3); 4) increases in GFAP
expression, the marker of reactive astrogliosis (Fig. 4 and Fig. 5).
Also genetic deletion of SphK1 possibly affects neuro and
gliogenesis (Figures S2 and S3).
SphK12/2 mice expressed increased inflammatory damage to
the brain induced by LPS as compared to wild type. The increased
neuroinflammation induced by LPS injection suggests that
absence of SphK1 gene and the consequent alteration of the
sphingolipid signaling pathway are responsible for the increased
inflammatory damage observed in the brains of SphK12/2 mice.
This corresponds with previous studies that showed that SphK1
triggers both the inflammatory response as well as LPS-activated
apoptosis [23,29,31,47]. The current study shows that the
presence of SphK1 is essential for maintaining neuroinflammatory
process under certain control.
Studies have shown a close correlation of S1P levels with the
expression of SphK1 and SphK2. Treatment with a SphK1
siRNA down-regulated serum levels of S1P in collagen-induced
arthritis mouse model [48]. Lower S1P levels were reported in
mice that had homozygous deletions of either SphK1 or SphK2
[49].
A variety of markers of brain injury show increased neuroin-
flammatory damage in SphK12/2 mice. White matter rarefac-
tions are increased in SphK12/2 mice intracerebrally injected
with LPS (Fig. 1). Development of rarefactions results from the loss
of white matter [7,50] and is associated with neuroinflammation
[39], oligodendrocyte loss and demyelination [40]. In the current
study, greater neuroinflammatory damage to white matter in
SphK12/2 mice injected with LPS was likely the result of
increased rarefactions and loss of O4+ oligodendrocyte progenitor
cells (Fig. 1 and Fig. 6). During neuroinflammation, TNFa can
induce oligodendrocytes loss [51]; the reduction of TNFa levels in
SphK12/2 animals may underlie why fewer oligodendrocytes
are lost following LPS injection [46,51]. In addition to activating
caspases, TNFa activates the transcription factor NFkB, which is
a potent survival signal. SphK may directly change TNFa
signaling toward the activation of NFkB through direct binding
of SphK1 with receptor associated factor (TRAF2) [52].
Edema leading to the enlargement of the lateral ventricles of the
brain is another hallmark of neuroinflammation. LPS loosens tight
junctions, and as a result cerebral ventricles enlarge [36,37].
Interestingly, the ventricular enlargement is also seen in control
saline intracerebrally injected SphK12/2 mice and in naı ¨ve
Figure 3. Immunohistochemistry using anti- CD 68 and ferritin light chain antibodies. (A) Two-way ANOVA analysis revealed significant
difference (*p=0.0451) in anti-CD68 (FITC) staining after LPS 1 mg/kg intracerebroventricular injection in wild type and SphK12/2 mice. (B)
Bonferroni’s multiple comparison of the anti-ferritin light chain staining (TRITC) determined significance between wild type LPS 1 mg/kg vs. SphK12/
2 LPS 1 mg/kg (**p=0.0181) and in mutant group after LPS injury (*p=0.0123).
doi:10.1371/journal.pone.0036475.g003
LPS Induced Severe Brain Inflammation
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36475Figure 4. (A) Immunohistochemistry of the frozen sections of the brains. GFAP specific antibody were used as a marker of reactive
astrocytes (arrows), propidium iodide was used as a marker of all cells in the studied lateral septal complex area of the animals’ brain. SphK12/2 mice
after LPS induction expressed the most of reactive astrocytes. Magnifications of 406 are shown. (B) Reactive astrocytes were quantified and
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SphK1 regulates the blood brain barrier (BBB) in the absence of
neuroinflammation. The role of S1P is well established in the
functions of vascular endothelium [53,54]. Lowered S1P levels are
hypothesized to derange cellular metabolism that leads to
impaired endothelial function and ventricular edema. In partic-
ular, earlier studies by Peng et al., (2004) and McVerry et al.,
(2004) have shown that infusion of S1P significantly decreases
pulmonary/renal vascular leakage and inflammation in a murine
model of LPS-mediated acute lung injury, which may represent
a novel therapeutic strategy for vascular barrier dysfunction.
Furthermore, exogenous S1P added to cultured neonatal rat
ventricular myocytes was protective against hypoxia-induced cell
death. Similarly, in an ex vivo mouse model, S1P administration via
aortic cannula before ischemia/reperfusion injury lead to
improved hemodynamics, reduced creatine kinase release, and
diminished infarct size. These results clearly suggest the mecha-
nism, which is common in preventing vascular leak and suggesting
the role for sphingosine kinases. However, if this is true or not in
brain tissue is not clear, and the effects of LPS induced brain injury
is rarely studied. If synthesis of S1P is highly dependent on its
phosphorylating enzyme SphK1, the functions of the end product
highly depend on the functions of the kinase. S1P stimulation
induces endothelial cell proliferation, migration and survival [55],
thus it is not a surprise that in our study we show a protection
provided by SphK1 on the extent of neuroinflammation, which
develops as a result of LPS injection into the ventricles of the
brain. In addition, an interesting study where bone marrow
derived progenitor cells (BMPC) were used to improve LPS
induced pulmonary edema revealed that BMPC from SphK12/
2 mice did not provide similar protection [56].
Usually, neuroinflammation is divided into acute and chronic.
Acute is considered to be somewhat beneficial, because it tends to
minimize further injury and contribute to the repair of damaged
tissue. It includes activation of the resident immune cells
(microglia) resulting in a phagocytic phenotype and the release
of inflammatory mediators such as cytokines and chemokines. In
contrast, chronic inflammation persists long after an initial injury
or insult. Microglia are activated for much longer period of times,
thus release of cytokines is longstanding. In addition, chronic
inflammation results in increased oxidative, nitrosative stress,
development of the leukoaraiosis, a loss of brain matter that
usually occurs as a result of ischemic injury [40,57] and is
connected to inflammation [39]. All these factors continue the
inflammatory cycle, activate additional microglia, promoting their
proliferation and result in further release of inflammatory factors.
Analysis of microglial activation provides additional evidence
that SphK1 negatively regulates neuroinflammation. LPS activates
microglia by binding to its receptor TLR-4 that is abundantly
present in the microglial membrane [58,59]. Microglia in the
brain are potently activated by LPS injected either intraperitone-
ally or intracerebrally, as seen using two markers of microglial
activation: CD68 and ferritin light chain (Fig. 2 and Fig. 3). Since
the BBB is likely compromised by LPS, it is not clear whether the
activated microglias are resident to the brain, or are from the
plasma [60]. Regardless of their origin, microglial activation is
greatly increased in SphK12/2 mice. Activated microglia can kill
oligodendrocytes. Therefore, increased microglial activation in
SphK12/2 mice may underlie the reduction in oligodendrocytes
and the development of white matter rarefactions.
Further evidence that SphK1 is a negative regulator of
inflammation comes from the analysis of glial activation and
cytokine expression [61]. Astrocytes of SphK12/2 mice express
enhanced levels of glial fibrillary acidic protein (GFAP) (Fig. 4 and
Fig. 5). Increased astroglial expression of GFAP is frequently
associated with activated microglia and elevated expression of
proinflammatory cytokines such as TNFa and IL-6 [34,44,51].
LPS treatment induces microglia and astrocytes to produce large
amounts of proinflammatory cytokines and chemokines [46,62].
Proinflammatory cytokines and chemokines trigger the sphingo-
statistically analyzed using two-way ANOVA. Significant results were reached in SphK12/2 groups after treatment with LPS 1 mg/kg (*p=0.0150).
SphK12/2 LPS 1 mg/kg injected animals expressed the highest number of the reactive astrocytes.
doi:10.1371/journal.pone.0036475.g004
Figure 5. (A) Western blot analysis of the GFAP protein expressed in the total brain extract. (B) Statistical analysis of the integrated
densities of the bands of the western blot. Significance was reached in wild type group after LPS induction (*p,0.0001) and in saline injected group
between wild type and SphK12/2 animals (**p,0.001).
doi:10.1371/journal.pone.0036475.g005
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S1P [20,63]. In astrocytes, S1P receptor activation leads to the
activation of extracellular signal-regulated kinase 1/2, which
results in cellular proliferation and neurotrophic factor production
as well as platelet derived growth factor (PDGF) production [64].
It is likely that there is increased production of proinflammatory
cytokines and chemokines in SphK12/2 mice which leads to
increased astrocyte activation.
Figure 6. Analysis of cortex area for oligodendrocyte expression. (A) Piriform cortex area of the analysis is depicted. Interaural: 4.39; bregma:
0.74. (B) Loss of oligodendrocytes (arrows) after intracerebroventricular injection of LPS 1 mg/kg in wild type and SphK12/2 mice. Nuclei were
stained with propidium iodide. 406magnifications are shown. (C) Number of oligodendrocytes was calculated per taken area of piriform cortex and
analyzed statistically. The significant loss of the oligodendrocytes was determined in wild type group after LPS 1 mg/kg was injected intracerebrally
(*p,0.0001) and between wild type saline and SphK12/saline groups (**p,0.001).
doi:10.1371/journal.pone.0036475.g006
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sphingosine (Fingolimod) FTY720, which was approved as
a sphingosine-1-phosphate receptor modulator in multiple sclero-
sis, induced remyelination and astrogliosis and that the action was
mediated via the S1P3 and S1P5 receptors, particularly through
the S1P5 which is highly expressed on mature oligodendrocytes.
SphK12/2 mice have fewer oligodendrocyte precursors than
wild-type mice (Fig. 6). SphK1 is essential for brain development
[49]. In our study, the absence of SphK1 may lead to altered
oligodendrocyte development. Alternatively, the finding of fewer
oligodendrocyte precursors in SphK12/2 mice may result from
an increased rate of apoptosis in these cells resulting in a higher
susceptibility of the CNS to LPS induced injury. It was shown
earlier that during neuroinflammation there is a certain loss of
oligodendrocytes [46]. Another study showed that TNFa mediates
loss of oligodendrocytes [51]. There are reports of a direct
interaction of SphK with TNF receptor associated factor
(TRAF2), suggesting the role of SphK in NFkB activation [52].
It is proposed that TNFa-induced activation of NFKB and JNK
most likely bifurcates at the site of TRAF2 binding. While SphK-
mediated TRAF2 promotes NFkB activation, JNK activation is
SphK-independent. Furthermore, we identified an inducible
interaction between Lyn kinase and SphK1 localized to lipid rafts
(data not shown). We demonstrated that during TNFR receptor
signaling SphK1 association with TNFR complex and its trans-
location to the lipid rafts plays an important role in SphK
activation and S1P synthesis. SphK1 is potently anti-apoptotic
[65] suggesting that SphK1 prevents apoptosis of oligodendrocytes
in the absence of LPS.
In the last few years, studies of sphingosine kinases have
generated a lot of controversy. For instance, a study published in
2006 showed that SphK1 is not required for inflammatory cell
recruitment during thioglycollate-induced peritonitis [66]. On the
other hand, numerous in vivo and in vitro studies where sphingosine
kinases were inhibited pharmacologically have demonstrated a role
of SphKs in triggering the inflammatory response, and that they
are responsible for LPS activated apoptosis [23,29,31,47]. We
believe that sphingosine kinase 1, a so-called pro-survival enzyme,
[67,68] can function as a modulator of inflammatory processes.
The presented data in this manuscript provides strong evidence
that SphK1 regulates neuroinflammation produced by a strong
inducer of inflammation, such as LPS. [67,68]. SphK1 also
regulated a neuroinflammatory like process in the absence of LPS.
SphK1 action is widespread in the brain with effects on the
vascular epithelium, astrocytes and microglia, and SphK1 is
essential for controlling the neuroinflammatory process.
This data along with earlier studies will be taken into
consideration for a further investigation of the possible mechan-
isms behind the development of the LPS-induced neuroinflamma-
tion and observed parameters such as leukoaraiosis, gliosis, and
loss of oligodendrocytes.
Supporting Information
Figure S1 Construction of the imaginary triangle inside
the lateral ventricle for the size quantification. Sizes of
both lateral ventricles of the brain were measured as areas of
a triangle (A=K of the base 6 height). Total area of the brain
section was taken as a 100 percent and percent taken by lateral
ventricles was calculated.
(TIF)
Figure S2 Hematoxylin and eosin staining of naı ¨ve wild
type and SphK12/2 animal’s brain slices. (A) Enlarged
ventricles (stars) are shown in SphK12/2 animals. Magnifica-
tions of 46 and 406 are shown. (B) Table represents mean 6
SEM (n=10) of the areas of lateral ventricles of the brains of wild
type and SphK12/2 mice. (C) Significant difference was found
between wild type and SphK12/2 mice, *p=0.0008.
(TIF)
Figure S3 (A) Immunohistochemical analysis of astro-
cyte specific protein GFAP in wild type and SphK12/2
naı ¨ve mice. (B) Statistical analysis of the expression of GFAP in
a series of images (n=6); *p,0.0001. (C) Western Blot analysis of
the GFAP protein, expressed by astrocytes. (D) Significant
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